Synonymous mutations in stem-loop III of Rev responsive elements enhance HIV-1 replication impaired by primary mutations for resistance to enfuvirtide

Antiviral Research

Volumn 82, Issue 1, 2009, Pages 67-72

  Ueno, Mariko ^a   Kodama, Eiichi N ^a   Shimura, Kazuya ^a   Sakurai, Yasuteru ^a   Kajiwara, Keiko ^a   Sakagami, Yasuko ^a   Oishi, Shinya ^a   Fujii, Nobutaka ^a   Matsuoka, Masao ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Fusion; gp41; HIV 1; Replication; Rev responsive element; Secondary mutation

Indexed keywords

ARGININE; CYTIDINE; ENFUVIRTIDE; GLYCOPROTEIN GP 41; GUANINE; VIRUS RNA;

ARTICLE; DNA RESPONSIVE ELEMENT; GENE MUTATION; GENE SEQUENCE; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REV RESPONSIVE ELEMENT; VIRUS GENOME; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; CELL LINE; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; PEPTIDE FRAGMENTS; POINT MUTATION; REV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 62049085108     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2009.02.002     Document Type: Article

References (40)

1. Armand-Ugón M., Gutiérrez A., Clotet B., and Esté J.A. HIV-1 resistance to the gp41-dependent fusion inhibitor C-34. Antiviral Res. 59 (2003) 137-142
2. Bishop K.N., Holmes R.K., Sheehy A.M., Davidson N.O., Cho S.J., and Malim M.H. Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr. Biol. 14 (2004) 1392-1396
3. Cabrera C., Marfil S., García E., Martinez-Picado J., Bonjoch A., Bofill M., Moreno S., Ribera E., Domingo P., Clotet B., and Ruiz L. Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen. AIDS 20 (2006) 2075-2080
4. Fikkert V., Cherepanov P., Van Laethem K., Hantson A., Van Remoortel B., Pannecouque C., De Clercq E., Debyser Z., Vandamme A.M., and Witvrouw M. env chimeric virus technology for evaluating human immunodeficiency virus susceptibility to entry inhibitors. Antimicrob. Agents Chemother. 46 (2002) 3954-3962
5. Fung H.B., and Guo Y. Enfuvirtide: a fusion inhibitor for the treatment of HIV infection. Clin. Ther. 26 (2004) 352-378
6. Hachiya A., Kodama E.N., Sarafianos S.G., Schuckmann M.M., Sakagami Y., Matsuoka M., Takiguchi M., Gatanaga H., and Oka S. Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors. J. Virol. 82 (2008) 3261-3270
7. Harris R.S., Bishop K.N., Sheehy A.M., Craig H.M., Petersen-Mahrt S.K., Watt I.N., Neuberger M.S., and Malim M.H. DNA deamination mediates innate immunity to retroviral infection. Cell 113 (2003) 803-809
8. Kimpton J., and Emerman M. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J. Virol. 66 (1992) 2232-2239
9. Kinomoto M., Yokoyama M., Sato H., Kojima A., Kurata T., Ikuta K., Sata T., and Tokunaga K. Amino acid 36 in the human immunodeficiency virus type 1 gp41 ectodomain controls fusogenic activity: implications for the molecular mechanism of viral escape from a fusion inhibitor. J. Virol. 79 (2005) 5996-6004
10. Kodama E.I., Kohgo S., Kitano K., Machida H., Gatanaga H., Shigeta S., Matsuoka M., Ohrui H., and Mitsuya H. 4′-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro. Antimicrob. Agents Chemother. 45 (2001) 1539-1546
11. Labrosse B., Morand-Joubert L., Goubard A., Rochas S., Labernardiére J.L., Pacanowski J., Meynard J.L., Hance A.J., Clavel F., and Mammano F. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients. J. Virol. 80 (2006) 8807-8819
12. Lalezari J.P., Henry K., O'Hearn M., Montaner J.S., Piliero P.J., Trottier B., Walmsley S., Cohen C., Kuritzkes D.R., Eron Jr. J.J., Chung J., DeMasi R., Donatacci L., Drobnes C., Delehanty J., and Salgo M. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J. Med. 348 (2003) 2175-2185
13. Lazzarin A., Clotet B., Cooper D., Reynes J., Arastéh K., Nelson M., Katlama C., Stellbrink H.J., Delfraissy J.F., Lange J., Huson L., DeMasi R., Wat C., Delehanty J., Drobnes C., and Salgo M. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N. Engl. J. Med. 348 (2003) 2186-2195
14. Liddament M.T., Brown W.L., Schumacher A.J., and Harris R.S. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr. Biol. 14 (2004) 1385-1391
15. Lu J., Deeks S.G., Hoh R., Beatty G., Kuritzkes B.A., Martin J.N., and Kuritzkes D.R. Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis. J. Acquir. Immune Defic. Syndr. 43 (2006) 60-64
16. Lu J., Sista P., Giguel F., Greenberg M., and Kuritzkes D.R. Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). J. Virol. 78 (2004) 4628-4637
17. Maeda Y., Venzon D.J., and Mitsuya H. Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance. J. Infect. Dis. 177 (1998) 1207-1213
18. Manfredi R., and Sabbatani S. A novel antiretroviral class (fusion inhibitors) in the management of HIV infection. Present features and future perspectives of enfuvirtide (T-20). Curr. Med. Chem. 13 (2006) 2369-2384
19. Mangeat B., Turelli P., Caron G., Friedli M., Perrin L., and Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424 (2003) 99-103
20. Marcelin A.G., Reynes J., Yerly S., Ktorza N., Segondy M., Piot J.C., Delfraissy J.F., Kaiser L., Perrin L., Katlama C., and Calvez V. Characterization of genotypic determinants in HR-1 and HR-2 gp41 domains in individuals with persistent HIV viraemia under T-20. AIDS 18 (2004) 1340-1342
21. Marcial M., Lu J., Deeks S.G., Ziermann R., and Kuritzkes D.R. Performance of human immunodeficiency virus type 1 gp41 assays for detecting enfuvirtide (T-20) resistance mutations. J. Clin. Microbiol. 44 (2006) 3384-3387
22. Mathews D.H., Sabina J., Zuker M., and Turner D.H. Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure. J. Mol. Biol. 288 (1999) 911-940
23. Menzo S., Castagna A., Monachetti A., Hasson H., Danise A., Carini E., Bagnarelli P., Lazzarin A., and Clementi M. Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment. Antimicrob. Agents Chemother. 48 (2004) 3253-3259
24. Mink M., Mosier S.M., Janumpalli S., Davison D., Jin L., Melby T., Sista P., Erickson J., Lambert D., Stanfield-Oakley S.A., Salgo M., Cammack N., Matthews T., and Greenberg M.L. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro. J. Virol. 79 (2005) 12447-12454
25. Morozov V.A., Morozov A.V., Schürmann D., Jessen H., and Kücherer C. Transmembrane protein polymorphisms and resistance to T-20 (Enfuvirtide, Fuzeon) in HIV-1 infected therapy-naive seroconverters and AIDS patients under HAART-T-20 therapy. Virus Genes 35 (2007) 167-174
26. Nameki D., Kodama E., Ikeuchi M., Mabuchi N., Otaka A., Tamamura H., Ohno M., Fujii N., and Matsuoka M. Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions. J. Virol. 79 (2005) 764-770
27. Olsen H.S., Nelbock P., Cochrane A.W., and Rosen C.A. Secondary structure is the major determinant for interaction of HIV rev protein with RNA. Science 247 (1990) 845-848
28. Otaka A., Nakamura M., Nameki D., Kodama E., Uchiyama S., Nakamura S., Nakano H., Tamamura H., Kobayashi Y., Matsuoka M., and Fujii N. Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells. Angew. Chem. Int. Ed. Engl. 41 (2002) 2937-2940
29. Pérez-Alvarez L., Carmona R., Ocampo A., Asorey A., Miralles C., Pérez de Castro S., Pinilla M., Contreras G., Taboada J.A., and Nájera R. Long-term monitoring of genotypic and phenotypic resistance to T20 in treated patients infected with HIV-1. J. Med. Virol. 78 (2006) 141-147
30. Poveda E., Rodés B., Toro C., Martín-Carbonero L., Gonzalez-Lahoz J., and Soriano V. Evolution of the gp41 env region in HIV-infected patients receiving T-20, a fusion inhibitor. AIDS 16 (2002) 1959-1961
31. Si-Mohamed A., Piketty C., Tisserand P., LeGoff J., Weiss L., Charpentier C., Kazatchkine M.D., and Bélec L. Increased polymorphism in the HR-1 gp41 env gene encoding the enfuvirtide (T-20) target in HIV-1 variants harboring multiple antiretroviral drug resistance mutations in the pol gene. J. Acquir. Immune Defic. Syndr. 44 (2007) 1-5
32. Sista P.R., Melby T., Davison D., Jin L., Mosier S., Mink M., Nelson E.L., DeMasi R., Cammack N., Salgo M.P., Matthews T.J., and Greenberg M.L. Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. AIDS 18 (2004) 1787-1794
33. Su C., Melby T., DeMasi R., Ravindran P., and Heilek-Snyder G. Genotypic changes in human immunodeficiency virus type 1 envelope glycoproteins on treatment with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitro. J. Clin. Virol. 36 (2006) 249-257
34. Svicher V., Aquaro S., D'Arrigo R., Artese A., Dimonte S., Alcaro S., Santoro M.M., Di Perri G., Caputo S.L., Bellagamba R., Zaccarelli M., Visco-Comandini U., Antinori A., Narciso P., Ceccherini-Silberstein F., and Perno C.F. Specific enfuvirtide-associated mutational pathways in HIV-1 gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure. J. Infect. Dis. 197 (2008) 1408-1418
35. Wei X., Decker J.M., Liu H., Zhang Z., Arani R.B., Kilby J.M., Saag M.S., Wu X., Shaw G.M., and Kappes J.C. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46 (2002) 1896-1905
36. Wiegand H.L., Doehle B.P., Bogerd H.P., and Cullen B.R. A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J. 23 (2004) 2451-2458
37. Xu L., Pozniak A., Wildfire A., Stanfield-Oakley S.A., Mosier S.M., Ratcliffe D., Workman J., Joall A., Myers R., Smit E., Cane P.A., Greenberg M.L., and Pillay D. Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41. Antimicrob. Agents Chemother. 49 (2005) 1113-1119
38. Zapp M.L., and Green M.R. Sequence-specific RNA binding by the HIV-1 Rev protein. Nature 342 (1989) 714-716
39. Zhang H., Yang B., Pomerantz R.J., Zhang C., Arunachalam S.C., and Gao L. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424 (2003) 94-98
40. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 31 (2003) 3406-3415